Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Blood (2025) 146 (Supplement 1): 256.

https://doi.org/10.1182/blood-2025-256

Published: 2025

Journal Articles

Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis

MacKenzie Mayo, Saumya Karne, Hyejeong Jang, Seongho Kim, Jose Maciel Larios, Dipenkumar Modi, Andrew Kin, Lois Ayash, Joseph Uberti, Abhinav Deol

Blood (2025) 146 (Supplement 1): 7832.

https://doi.org/10.1182/blood-2025-7832

Published: 2025

Journal Articles

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Divaya Bhutani, Shami Chakrabarti, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Markus Mapara, Abhinav Deol, Joseph Uberti, Ran Reshef

Blood (2025) 146 (Supplement 1): 4062.

https://doi.org/10.1182/blood-2025-4062

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma

Kyle Sugg, Hyejeong Jang, Seongho Kim, Jose Maciel Larios, Andrew Kin, Lois Ayash, Joseph Uberti, Dipenkumar Modi, Abhinav Deol

Blood (2025) 146 (Supplement 1): 7807.

https://doi.org/10.1182/blood-2025-7807

Published: 2025

Journal Articles

Race does not impact chimeric antigen receptor T-cell therapy outcomes for multiple myeloma and diffuse large B cell lymphoma

Anisha Rajavel, Sushmitha Nanja Reddy, Saumya Karne, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Lois Ayash, Dipenkumar Modi, Andrew Kin, Joseph Uberti, Abhinav Deol

Blood (2025) 146 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2025-6327

Published: 2025

Journal Articles

Outcomes of outpatient chimeric antigen receptor T-cell therapy administration: A single center experience at an urban hospital

Anisha Rajavel, Saumya Karne, Sushmitha Nanja Reddy, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Lois Ayash, Dipenkumar Modi, Andrew Kin, Joseph Uberti, Abhinav Deol

Blood (2025) 146 (Supplement 1): 6329.

https://doi.org/10.1182/blood-2025-6329

Published: 2025

Journal Articles

Race matters: Cytopenia trajectories after chimeric antigen receptor T- cell therapy in a single-center study

Sushmitha Nanja Reddy, Anisha Rajavel, Saumya Karne, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Andrew Kin, Lois Ayash, Joseph Uberti, Dipenkumar Modi, Abhinav Deol

Blood (2025) 146 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2025-4170

Published: 2025

Journal Articles

Non-relapse mortality in patients who received CAR T-cell therapy at an urban hospital

Saumya Karne, Anisha Rajavel, Sushmitha Nanja Reddy, Janaka Liyanage, Seongho Kim, Jose Maciel Larios, Lois Ayash, Andrew Kin, Joseph Uberti, Dipenkumar Modi, Abhinav Deol

Blood (2025) 146 (Supplement 1): 4160.

https://doi.org/10.1182/blood-2025-4160

Published: 2025

Journal Articles

A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)

Aditi Sharma, Joel Topf, Christiane A. Houde, Cathy Galasso, Sarah Phillips, Carmen Mitteer, Amanda Guido, Lori McFadden, Katelyn Staub, Amy Blake, Joseph Ellul, Andrew Kin, Craig Emmitt Cole, Abhinav Deol, Joseph Schiavi, Seongho Kim, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 1927.2.

https://doi.org/10.1182/blood-2024-211533

Published: 2024

Journal Articles

Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Abhinav Deol, Taha Mahdi Salih Al-Juhaishi, Premal D. Lulla, Michael T. Byrne, Carol Wong, Cara Bickers, Trever Greene, Lilly Wong, Bertha Villa, Deepa Patel, Bahram Bob Valamehr, Rebecca Elstrom, Matthew Lunning

Blood (2024) 144 (Supplement 1): 6543.

https://doi.org/10.1182/blood-2024-198684

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Blood (2024) 144 (Supplement 1): 887.

https://doi.org/10.1182/blood-2024-200339

Published: 2024

Journal Articles

Trial in Progress: Iberdomide and Daratumumab As Maintenance Therapy after an Autologous Stem Cell Transplant for Multiple Myeloma (the IBEX Trial)

Andrew Kin, Jeffrey A. Zonder, Craig Emmitt Cole, Abhinav Deol, Suresh Kumar Balasubramanian, Seongho Kim, Christiane A. Houde, Joseph Ellul, Amy Blake, Katelyn Staub, Amanda Guido, Erik Carr, Sarah Phillips, Julie Boerner

Blood (2024) 144 (Supplement 1): 7007.

https://doi.org/10.1182/blood-2024-210562

Published: 2024

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-r AML

Md. Hafiz Uddin, Amro Aboukameel, Sharif hasan Siddiqui, Husain Khan, Sahar Bannoura, Abhinav Deol, Jay Yang, Gregory Dyson, Asfar Azmi, Lisa Polin, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian

Blood (2023) 142 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2023-190638

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

Journal Articles

Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data

Sattva S. Neelapu, L. Elizabeth Budde, Joseph P McGuirk, Saurabh Dahiya, Abhinav Deol, Philip A. Thompson, Nitin Jain, Matthew A Lunning, Xiaomeng Hu, Boris Gorovits, Danielle Quarles, Barbara Metallo, Meghan Flaherty, Weidong Zhang, Hosein Kouros-Mehr, Terry J. Fry, Sonja Schrepfer

Blood (2023) 142 (Supplement 1): 6852.

https://doi.org/10.1182/blood-2023-179441

Published: 2023

Journal Articles

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

Asmita Shukla, Seongho Kim, Hyejeong Jang, Andrew Kin, Aasiya Matin, Lois Ayash, Abhinav Deol, Voravit Ratanatharathorn, Joseph Uberti, Dipenkumar Modi

Blood (2023) 142 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2023-190562

Published: 2023

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Journal Articles

Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin's Lymphoma?

Abdul Moiz Khan, Neha Venkatesh, Joseph P. Uberti, Voravit Ratanatharathorn, Dipenkumar Modi, Lois Ayash, Asif Alavi, Andrew Kin, Aasiya Matin, Abhinav Deol

Blood (2022) 140 (Supplement 1): 7565–7566.

https://doi.org/10.1182/blood-2022-164618

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma

Race does not impact chimeric antigen receptor T-cell therapy outcomes for multiple myeloma and diffuse large B cell lymphoma

Outcomes of outpatient chimeric antigen receptor T-cell therapy administration: A single center experience at an urban hospital

Race matters: Cytopenia trajectories after chimeric antigen receptor T- cell therapy in a single-center study

Non-relapse mortality in patients who received CAR T-cell therapy at an urban hospital

A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)

Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

Trial in Progress: Iberdomide and Daratumumab As Maintenance Therapy after an Autologous Stem Cell Transplant for Multiple Myeloma (the IBEX Trial)

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-r AML

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data

Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin's Lymphoma?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only